anti-Cspg4 antibody fused with IFN type I (UCLA)

N/A

Report date: 2025/03/14 16:55:26

Base Information

Drug Nameanti-Cspg4 antibody fused with IFN type I (UCLA)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionChondroitin sulfate proteoglycan 4 inhibitors
TargetsChondroitin sulfate proteoglycan 4
Therapy Area/IndicationsTriple Negative Breast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California, Los Angeles
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of CaliforniaUniversity Of California, Los Angeles
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A